Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Mossad unveils network of Hamas terror infrastructure across Europe - 2People who talk with their hands seem more clear and persuasive – new research
- 3Trump said affordability is a ‘hoax’ in his Pennsylvania speech. What do the latest numbers show?
- 4Saturn shines with the waxing moon at sunset on Nov. 29
- 5Pentagon advances Golden Dome missile defense with new Space Force contracts
- France will build a new aircraft carrier as it increases defense spending
- Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- Dental, Vision, and Hearing Inclusion in Senior Protection.
- Figure out How to Reveal Stowed away Open Record Rewards
- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- The Manual for Electric Vehicles that will be hot dealers in 2023
- Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
- Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- Select Your Cherished Fish
